Market for Atopic Dermatitis Treatments to Surge Past $22 Billion

The global atopic dermatitis (AD) market is projected to more than double over the next decade, reaching $22.37 billion by 2034, new research from Polaris Market Research indicates.

Driven by an annual growth rate of 8.5%, the report says the AD landscape is experiencing significant momentum due to increasing disease prevalence and the advancement of biologics. The market is estimated at $9.93 billion in 2024 and is expected to steadily expand over the next 10 years.

According to the International Eczema Council, approximately 223 million individuals worldwide were affected by AD in 2022. The report notes that while AD primarily affects children, it persists into adulthood for many and is often comorbid with conditions such as asthma, allergic rhinitis, and food allergies.

The report said the market remains highly competitive, with leading manufacturers including Regeneron Pharmaceuticals, Sanofi, AbbVie, Pfizer, Eli Lilly, Incyte, Galderma, and LEO Pharma. 

Source: Polaris Market Research and Consulting press release. May 5, 2025.